From Data to Action: Study Identifying Determinants of Short Birth Intervals

Recent study focused on predicting short birth intervals (defined as less than 33 months) among reproductive-age women in East Africa, using supervised machine learning (ML) models to identify key determinants. Utilized recent Demographic and Health Surveys (DHS) data from 11 East African countries, including Uganda and Ethiopia, with a sample size of 100,246 women who had at least two consecutive live births. Implemented a two-stage stratified cluster sampling technique to ensure representation of both urban and rural populations. Employed various techniques, including data cleaning, normalization, feature selection through Recursive Feature Elimination (RFE), and handling missing data via mode imputation. Continuous variables were discretized for improved model interpretability. Utilized Python libraries (Pandas, scikit-learn) to build models, including Random Forest (RF), Decision Tree (DT), Logistic Regression (LR), and Naive Bayes (NB). The dataset was split into training (80%) and testing (20%) sets for evaluation. The Random Forest model achieved the highest accuracy (79.4%), precision (79.0%), recall (91%), and F1-score (84%), outperforming DT and LR. Important factors included: – -Age-: Women aged 15-24 had higher risks of short birth intervals. Higher risks were associated with having 2-3 children. Women from poorer households exhibited increased rates of short intervals. Lack of education correlated with shorter birth spacing. Limited access and exposure influenced family planning decisions. The reliance on self-reported data from DHS, which could lead to potential biases. The findings may not fully represent populations in regions not included in the study. Although supervised ML models were effective, the inherent complexity might not be easily interpretable for public health practitioners. The study successfully applied machine learning to predict short birth intervals and uncover significant determinants, emphasizing the need for enhanced family planning services and maternal education in East Africa. Recommendations included integrating ML models into public health strategies to inform policy-making and improve maternal and child health outcomes. The research underscores the importance of addressing underlying socioeconomic factors to improve birth spacing practices.

Key Points

– -Data Utilization and Methodology-: Analyzed data from Demographic and Health Surveys (DHS) across 11 East African countries, focusing on a robust sample of 100,246 women with at least two consecutive live births. A two-stage stratified cluster sampling ensured diverse representation from urban and rural areas.

– -Data Processing Techniques-: Implemented comprehensive data preprocessing methods, including cleaning and normalization, feature selection via Recursive Feature Elimination (RFE), and mode imputation for missing values. Continuous variables were transformed for better model interpretability.

– -Modeling Approach-: Employed various supervised machine learning algorithms such as Random Forest, Decision Tree, Logistic Regression, and Naive Bayes, utilizing Python libraries for model development. The dataset was partitioned into training (80%) and testing (20%) sets, facilitating thorough evaluation of model performance.

– -Performance Metrics-: The Random Forest model demonstrated superior efficacy, achieving an accuracy of 79.4%, precision of 79.0%, recall of 91%, and an F1-score of 84%, surpassing the performance of the other modeling approaches.

– -Determinants of Short Birth Intervals-: Identified critical factors influencing short birth intervals, highlighting that younger women (15-24 years), those with 2-3 children, lower socioeconomic status, lack of maternal education, and restricted access to healthcare and media exposure were significantly associated with increased risks of shorter birth spacing.

– -Recommendations and Policy Implications-: Encouraged the integration of machine learning techniques into public health frameworks to enhance family planning services and promote maternal education. The study emphasized addressing socioeconomic factors to improve birth-spacing practices and overall maternal and child health outcomes in East Africa.

Reference –

Tirualem Zeleke Yehuala et al. (2025). Exploring Machine Learning Algorithms To Predict Short Birth Intervals And Identify Its Determinants Among Reproductive-Age Women In East Africa. *BMC Pregnancy And Childbirth*, 25. https://doi.org/10.1186/s12884-025-07668-z.

Powered by WPeMatico

NEET MDS: KNRUHS to end Online Registration After Cut-Off Reduction, details

Telangana- The Kaloji Narayan Rao University of Health Sciences (KNRUHS) has issued a notification regarding the online registration after the reduction of the cut-off score for the Master of Dental Surgery (MDS) admission under the Competent Authority and Management Quota for the academic year 2025-26.

KNRUHS has notified on the online registration from NEET-MDS- 2025 qualified candidates for admission into MDS courses under Competent Authority into Dental Colleges and Management Quota MQ1, MQ2 (NRI), MQ3 categories for the academic year 2025-26 into affiliated Private Dental colleges in Telangana State including Army College of Dental Sciences.

Notification is issued for online registration for web-based counselling to update the State Merit position for admission into Competent Authority Quota and Management Quota seats only. The Updated Final Merit list will be notified after scrutiny of all certificates uploaded at the time of online registration. The total number of vacant seats available under the Competent Authority Quota and the Management Quota for the academic year 2025-26 will be notified on the KNRUHS website before exercising web options for counselling. Tuition fee payable will be as notified by the Government of Telangana.

REVISED CUT-OFF SCORE IN NEET-MDS-2025 EXAM FOR MDS COURSES

Candidates should have secured the following cutoff score or above in NEET-MDS-2025-

S.NO

CATEGORY

MINIMUM ELIGIBILITY CRITERIA

REVISED CUT-OFF SCORE

1

General Category

30.137 Percentile 197

168

2

General – PWD

25.137 Percentile

182

3

SC/ST/OBC (including PWD of SC/ST/OBC)

20.137 Percentile

168

Meanwhile, as per the notification, the candidates can register online and upload scanned certificates on the official website of KNRUHS from 4.00 PM on 21 August 2025 up to tomorrow, i.e. 23 August 2025, 01.00 PM.

Provisional Final Merit position of the applied candidates will be prepared based on NEET-MDS–2025 Rank and other eligibility criteria notified hereunder. However, candidates who have already registered previously under the Competent Authority and the Management Quota need not register again.

To view the notifications, click the link below

https://medicaldialogues.in/pdf_upload/notification-1-298469.pdf

Powered by WPeMatico

Ravenbhel’s Bilastine, Montelukast FDC Under Review, CDSCO Panel Seeks Pediatric Expert Opinion

New Delhi: In response to a proposal submitted by Ravenbhel Healthcare of the fixed dose combination (FDC) pulmonary drug Bilastine 10 mg plus Montelukast Sodium IP eq. to Montelukast 4 mg per 5 mL oral solution, the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended inviting a pediatrician for a detailed discussion on the matter.

This came after the firm presented the proposal along with justification for BE and Phase III CT waiver before the committee.

Bilastine is an antihistamine medication used to treat hives (urticaria), allergic rhinitis and itchy inflamed eyes (allergic conjunctivitis) caused by an allergy. It is a second-generation antihistamine and takes effect by selectively inhibiting the histamine H1 receptor, preventing these allergic reactions.

Montelukast is in a class of medications called leukotriene receptor antagonists (LTRAs). It works by blocking the action of substances in the body that cause the symptoms of asthma and allergic rhinitis.

Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.

At the recent SEC meeting for Pulmonary held on the 7th August 2025, the expert panel reviewed the proposal along with justification for BE and Phase III CT waiver before the committee.

After detailed deliberation, the committee opined that Pediatrician may be invited in next meeting for wider discussion in the matter.

Also Read: Sun Pharma’s Dapagliflozin, Glimepiride, Metformin FDC Fails to Secure CDSCO Panel Nod Over Safety, Utility Concerns

Powered by WPeMatico

Low daily fluid intake linked to higher stress hormone response in adults

People who drink less than the recommended daily fluid intake experience a greater stress hormone response, which is associated with an increased risk of heart disease, diabetes and depression, according to a new study from scientists in Liverpool, U.K.

Powered by WPeMatico

Merck’s SpringWorks Therapeutics gets nod for Ogsiveo from European Commission for adults with Desmoid Tumors

Stamford: SpringWorks Therapeutics, Inc., a healthcare company of Merck, has received marketing authorization from the European Commission for OGSIVEO (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. OGSIVEO is a therapy approved in the European Union (EU) to treat desmoid tumors.

“Desmoid tumors can have a profound impact on people’s lives and are difficult to manage due to their invasive nature and high rates of recurrence. Until now, there have been no approved medicines in Europe,” said Bernd Kasper, M.D., Ph.D., Professor, University of Heidelberg, Mannheim Cancer Center, Mannheim, Germany, and principal investigator of the DeFi trial. “OGSIVEO is a highly innovative therapy with efficacy data demonstrating both meaningful antitumor activity and a significant improvement in desmoid tumor symptoms, including a significant reduction in pain which is the most debilitating symptom reported by patients.”

“This approval is a long-awaited advance for desmoid tumor patients, their families and physicians in Europe,” said Lynne Hernandez, Executive Director of the Desmoid Tumor Research Foundation. “It is our hope that patients will benefit from greater awareness of desmoid tumors, faster diagnoses, and better outcomes now that there is an approved treatment.”

Desmoid tumors are rare, locally aggressive tumors that form in the connective tissues of the body. Approximately 1,300 to 2,300 new cases of desmoid tumors are diagnosed annually in the EU. These tumors can cause severe pain, limited function, loss of mobility, disfigurement and fatigue. They are challenging to manage because of their unpredictable nature and high rate of recurrence, which can significantly impact an individual’s quality of life. Desmoid tumor experts and treatment guidelines now recommend medical therapy as first-line intervention instead of surgery for most tumor locations requiring treatment.

“We would like to extend our gratitude to the patients, families, investigators, and advocacy organizations who helped make this EC approval possible,” said Danny Bar-Zohar, MD, CEO of Healthcare and Executive Board Member at Merck KGaA, Darmstadt, Germany. “OGSIVEO is already established as the standard of care systemic therapy for desmoid tumors in the U.S., and our goal is to bring the same treatment benefits to patients in Europe. Following last month’s EC approval of our therapy for patients with NF1-PN, we are in the unique position of launching two innovative treatments — underscoring our commitment to the rare tumor patient community.”

The EC approval of OGSIVEO is based on results from the Phase 3 DeFi trial, which enrolled 142 adult patients with progressing desmoid tumors and met the primary endpoint of improving progression-free survival (PFS). OGSIVEO demonstrated a statistically significant improvement over placebo with a 71% reduction in the risk of disease progression (hazard ratio (HR) = 0.29 (95% CI: 0.15, 0.55); p< 0.001). OGSIVEO also demonstrated a significant improvement in objective response rate (ORR). The confirmed ORR based on RECIST v1.1 was 41% with OGSIVEO versus 8% with placebo (p<0.001); the complete response rate was 7% in the OGSIVEO arm and 0% in the placebo arm. The median time to first response was 5.6 months with OGSIVEO and 11.1 months with placebo. Additionally, OGSIVEO demonstrated early and sustained improvement in patient-reported outcomes (PROs), including pain (p<0.001), desmoid tumor-specific symptoms (p<0.001), physical/role functioning (p<0.001), and overall health-related quality of life (p≤0.01).

OGSIVEO exhibited a manageable safety and tolerability profile.

The FDA and the EMA have granted Orphan Drug designation for OGSIVEO for the treatment of desmoid tumors.

Powered by WPeMatico

Hemoglobin’s antioxidant role in brain cells points to new therapeutic avenue

Hemoglobin, long celebrated for ferrying oxygen in red blood cells, has now been revealed to play an overlooked—and potentially game-changing—antioxidant role in the brain.

Powered by WPeMatico

Global study shows racialized, Indigenous communities face higher burden of heart disease made worse by data gaps

A new study has revealed that racialized and Indigenous communities across Europe, North America, and Central America face significantly higher rates of cardiovascular disease (CVD), and that gaps in health care data are making the problem worse.

Powered by WPeMatico

NEET PG 2025 answer key soon! check complete details

New Delhi- The National Board of Examinations in Medical Sciences (NBEMS) is soon going to publish the answer key of the National Eligibility and Entrance Test-Postgraduate (NEET PG) exam for the academic year 2025.

NBE declared the NEET-PG 2025 exam result recently on 19th August 2025.

According to the notice issued by the NBEMS in this regard, the NEET-PG 2025 exam answer key will be published as the Hon’ble Supreme Court has directed to publish the raw scores, answer keys and normalisation formulae for transparency in multi-shift NEET-PG exams.

Therefore, as per the Supreme Court direction, NBEMS will publish the answer key of NEET-PG 2025 on its official website. Along with the correct answer key, the responses marked by the candidates to the respective questions asked in NEET-PG 2025 will also be published. The score given for each of the questions as per the scheme of evaluation detailed in the Information Bulletin of NEET-PG 2025 will be mentioned too.

After the publication of the NEET-PG 2025 exam answer key, the candidates who have appeared in the NEET-PG 2025 shall be able to access the Answer Key and his/her marked responses through their applicant login at the NEET-PG 2025 index page at the NBEMS website.

Meanwhile, the notice also added that since the sequence of questions asked within a section are shuffled for different candidates and the order of four distractors of a question are also shuffled for different candidates appearing in NEET-PG 2025, the question ID Numbers, correct answer key and responses marked shall be displayed as per Master set of Question Paper used for NEET-PG 2025.

Moreover, NBEMS is in the process of developing an online portal to display the answer keys and responses marked. The same shall be made live at the earliest possible time.

To view the notice, click the link below

https://medicaldialogues.in/pdf_upload/nbe-to-release-neet-pg-2025-answer-key-soon-following-supreme-courts-directive-298427.pdf

Powered by WPeMatico

Fortis expands Uttar Pradesh Footprint with 550-bed Hospital in Lucknow

Lucknow: Fortis Healthcare has signed a collaboration agreement with Ekana Group, Lucknow, for operations and management of a 550-bedded greenfield super speciality hospital to be constructed near Gomti Nagar, Lucknow by the Ekana Group. 

Once completed, the facility will be positioned as Centre of Excellence for tertiary care services, bringing advanced medical infrastructure and global best practices to the state capital of Uttar Pradesh.

Speaking on the collaboration, Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, said, “We are delighted to partner with Ekana Group to bring a state-of-the-art tertiary healthcare facility to the heart of Lucknow.

Also Read:Fortis acquires Shrimann Superspecialty Hospital in Jalandhar for Rs 462 crore

Once operational, this new 550‑bed super‑specialty hospital near Gomti Nagar will significantly enhance access to advanced medical care for the city and its surrounding regions.

This collaboration marks Fortis Healthcare’s third major presence in Uttar Pradesh, joining our network hospitals in Noida and Greater Noida and underscores our steadfast commitment to expanding high‑quality healthcare across the state.”

Mr. Uday Sinha, Promoter of Ekana Group, said, “We are happy to join hands with one of the leading healthcare chains in India – Fortis Healthcare to develop a leading-edge tertiary care hospital, one that will significantly enhance access to advanced medical services and deliver patient care where it’s most needed.”

Medical Dialogues had earlier reported that in yet another clinical milestone, Fortis Hospital, Bannerghatta Road, Bengaluru, has advanced its robot-aided infrastructure with the launch of the TREAT program (Total Robot Enabled and Assisted Transplant) – a pioneering initiative in robot-assisted kidney transplantation. This state-of-the-art initiative marks a major leap forward in surgical excellence and patient care, especially with its historic milestone: the successful execution of simultaneous robotic surgeries for both donor and recipient — a first-of-its-kind clinical achievement in India.

Also Read:Manipal Outbids Blackstone, Fortis to Lead Race for Sahyadri Hospitals with Rs 6,838 Cr Offer

Powered by WPeMatico

AI-Powered Lifestyle System Reduces HbA1C and Medication dependence in Type 2 Diabetes: Study

Researchers have found in a new study that an AI-based personalized lifestyle management system could help patients with type 2 diabetes lower HbA1c levels and reduce dependence on glucose-lowering medications, offering a scalable and affordable approach to diabetes care. The study was published in the NEJM Catalyst Innovations in Care Delivery by Kevin M. and colleagues.

Even with significant progress in pharmacological treatments and digital health technologies, optimal glycemic control in T2D is still a worldwide challenge to reach and maintain. Lifestyle interventions are successful but hard to sustain in everyday clinical practice. Artificial intelligence (AI) and machine learning (ML) now offer the possibility of providing highly personalized and pragmatic advice that fills the gap between doctor’s recommendations and patient behavior.

The Twin Precision Treatment system combines wearables with Bluetooth-enabled devices (such as continuous glucose monitors), focused laboratory data, Internet of Things, AI-ML algorithms, and human guidance to deliver real-time, patient-specific advice.

This single-center randomized controlled trial recruited 150 adults with T2D with a body mass index (BMI) of ≥27. Participants were randomly assigned in a 2:1 ratio to the intervention group (INT, N=100) or the usual care group (UC, N=50). The main endpoint was to reach HbA1c <6.5% (<48 mmol/mol) off glucose-lowering therapy (other than metformin) at 12 months.

Secondary endpoints were:

• Maintenance of HbA1c <6.5% off medications for ≥90 days before 12 months

• Reaching HbA1c <6.5% off any glucose-lowering medications at 12 months and maintained ≥90 days

• HbA1c and weight change at 12 months

• Post hoc analyses of medication usage and quality-of-life scores.

Key Findings

Primary endpoint:

• Attained by 71.0% of INT participants (95% CI, 60.1–80.0)

• Attained by just 2.4% of UC participants (95% CI, 0.5–11.6)

• P<0.001

Glycemic target sustained ≥90 days before 12 months (except metformin):

• 52.5% in INT vs. 2.8% in UC (P<0.001)

Reduction in HbA1c at 12 months:

• INT: −1.3%

• UC: −0.3%

• P<0.001

Weight loss at 12 months:

• INT: −8.6%

• UC: −4.6%

• P<0.001

Medication use:

• Significant reduction in glucose-lowering pharmacotherapy in INT group

• No change of significance in UC group

• Quality of life and treatment satisfaction

• Mean improvement in INT group (exploratory analysis)

• No improvement in UC group

In this randomized trial of 150 adults with T2D, an AI-supported bundled system of sensors and coaching resulted in much more improved glycemic control, weight loss, and quality of life compared to standard care. Most importantly, it enabled huge de-escalation of glucose-lowering drugs, with 71% attaining HbA1c <6.5% off all medications except metformin versus 2.4% in controls. These findings demonstrate the revolutionary potential of precision medicine based on AI in type 2 diabetes treatment.

Reference:

Pantalone, K. M., Xiao, H., Bena, J., Morrison, S., Downie, S., Boyd, A. M., Shah, L., Willis, B., Beharry-Diaz, J., Milinovich, A., Joshi, S., Kaufman, F. R., & Mechanick, J. I. (2025). Type 2 diabetes pharmacotherapy DE-escalation through AI-enabled lifestyle modifications: A randomized clinical trial. NEJM Catalyst Innovations in Care Delivery, 6(9). https://doi.org/10.1056/cat.25.0016

Powered by WPeMatico